{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:44:25Z","timestamp":1790858665372,"version":"4.1.0"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p>Muscle repair and regeneration are complex processes. In Duchenne muscular dystrophy (DMD), these processes are disrupted by the loss of functional dystrophin, a key part of the transmembrane dystrophin-associated glycoprotein complex that stabilizes myofibers, indirectly leading to progressive muscle wasting, subsequent loss of ambulation, respiratory and cardiac insufficiency, and premature death. As part of the DMD pathology, histone deacetylase (HDAC) activity is constitutively increased, leading to epigenetic changes and inhibition of muscle regeneration factors, chronic inflammation, fibrosis, and adipogenesis. HDAC inhibition has consequently been investigated as a therapeutic approach for muscular dystrophies that, significantly, works independently from specific genetic mutations, making it potentially suitable for all patients with DMD. This review discusses how HDAC inhibition addresses DMD pathophysiology in a multi-targeted mode of action and summarizes the recent evidence on the rationale for HDAC inhibition with givinostat, which is now approved by the United States Food and Drug Administration for the treatment of DMD in patients aged 6\u00a0years and older.<\/jats:p>","DOI":"10.3389\/fcell.2024.1514898","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T07:05:00Z","timestamp":1736147100000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Histone deacetylase inhibition with givinostat: a multi-targeted mode of action with the potential to halt the pathological cascade of Duchenne muscular dystrophy"],"prefix":"10.3389","volume":"12","author":[{"given":"A.","family":"Aartsma-Rus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1089\/hum.2023.026","article-title":"The future of exon skipping for Duchenne muscular dystrophy","volume":"34","author":"Aartsma-Rus","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1136\/jmedgenet-2015-103387","article-title":"The importance of genetic diagnosis for Duchenne muscular dystrophy","volume":"53","author":"Aartsma-Rus","year":"2016","journal-title":"J. Med. Genet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.coi.2011.07.002","article-title":"Histone\/protein deacetylases control Foxp3 expression and the heat shock response of T-regulatory cells","volume":"23","author":"Beier","year":"2011","journal-title":"Curr. Opin. Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.nmd.2016.07.002","article-title":"Histological effects of givinostat in boys with Duchenne muscular dystrophy","volume":"26","author":"Bettica","year":"2016","journal-title":"Neuromuscul. Disord."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1183101","DOI":"10.3389\/fphys.2023.1183101","article-title":"Duchenne muscular dystrophy: disease mechanism and therapeutic strategies","volume":"14","author":"Bez Batti Angulski","year":"2023","journal-title":"Front. Physiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3109\/08977194.2011.595714","article-title":"TGF-\u03b2 signaling in fibrosis","volume":"29","author":"Biernacka","year":"2011","journal-title":"Growth factors."},{"key":"B7","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/humu.22758","article-title":"The TREAT-NMD DMD global database: analysis of more than 7,000 Duchenne muscular dystrophy mutations","volume":"36","author":"Bladen","year":"2015","journal-title":"Hum. Mutat."},{"key":"B8","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1152\/physrev.00028.2001","article-title":"Function and genetics of dystrophin and dystrophin-related proteins in muscle","volume":"82","author":"Blake","year":"2002","journal-title":"Physiol. Rev."},{"key":"B9","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/nm.3918","article-title":"The central role of muscle stem cells in regenerative failure with aging","volume":"21","author":"Blau","year":"2015","journal-title":"Nat. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/emmm.201100133","article-title":"miRNAs as serum biomarkers for Duchenne muscular dystrophy","volume":"3","author":"Cacchiarelli","year":"2011","journal-title":"EMBO Mol. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/338259a0","article-title":"Association of dystrophin and an integral membrane glycoprotein","volume":"338","author":"Campbell","year":"1989","journal-title":"Nature"},{"key":"B12","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.stem.2018.03.022","article-title":"The dystrophin glycoprotein complex regulates the epigenetic activation of muscle stem cell commitment","volume":"22","author":"Chang","year":"2018","journal-title":"Cell. Stem Cell."},{"key":"B13","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2119\/molmed.2013.00011","article-title":"Preclinical studies in the mdx mouse model of Duchenne muscular dystrophy with the histone deacetylase inhibitor givinostat","volume":"19","author":"Consalvi","year":"2013","journal-title":"Mol. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"11856","DOI":"10.4081\/ejtm.2023.11856","article-title":"Cellular pathogenesis of Duchenne muscular dystrophy: progressive myofibre degeneration, chronic inflammation, reactive myofibrosis and satellite cell dysfunction","volume":"33","author":"Dowling","year":"2023","journal-title":"Eur. J. Transl. Myol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B16","article-title":"DMD treatment Givinostat reaches important stage in European approval process","year":"2023"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1038\/nm.3990","article-title":"Dystrophin expression in muscle stem cells regulates their polarity and asymmetric division","volume":"21","author":"Dumont","year":"2015","journal-title":"Nat. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1083\/jcb.122.4.809","article-title":"A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin","volume":"122","author":"Ervasti","year":"1993","journal-title":"J. Cell. Biol."},{"key":"B19","first-page":"1","article-title":"Epigenetic regulation of osteogenic and chondrogenic differentiation of mesenchymal stem cells in culture","volume":"15","author":"Eslaminejad","year":"2013","journal-title":"Cell."},{"key":"B20","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2119\/molmed.2011.00020","article-title":"Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat)","volume":"17","author":"Furlan","year":"2011","journal-title":"Mol. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"16456","DOI":"10.1073\/pnas.1910456117","article-title":"Premature termination codons in the DMD gene cause reduced local mRNA synthesis","volume":"117","author":"Garc\u00eda-Rodr\u00edguez","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1093\/hmg\/ddu735","article-title":"Toll-like receptor 4 ablation in mdx mice reveals innate immunity as a therapeutic target in Duchenne muscular dystrophy","volume":"24","author":"Giordano","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"B23","doi-asserted-by":"publisher","first-page":"6484","DOI":"10.1111\/febs.16080","article-title":"Signaling pathways regulating the fate of fibro\/adipogenic progenitors (FAPs) in skeletal muscle regeneration and disease","volume":"289","author":"Giuliani","year":"2022","journal-title":"FEBS J."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1113\/EP085308","article-title":"Advances in genetic therapeutic strategies for Duchenne muscular dystrophy","volume":"100","author":"Guiraud","year":"2015","journal-title":"Exp. Physiol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1093\/hmg\/ddt656","article-title":"Role of Toll-like receptors in the pathogenesis of dystrophin-deficient skeletal and heart muscle","volume":"23","author":"Henriques-Pons","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"B26","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","article-title":"Dystrophin: the protein product of the Duchenne muscular dystrophy locus","volume":"51","author":"Hoffman","year":"1987","journal-title":"Cell."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s40265-023-01929-x","article-title":"Delandistrogene moxeparvovec: first approval","volume":"83","author":"Hoy","year":"2023","journal-title":"Drugs"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1180980","DOI":"10.3389\/fphys.2023.1180980","article-title":"Satellite cell contribution to disease pathology in Duchenne muscular dystrophy","volume":"14","author":"Kodippili","year":"2023","journal-title":"Front. Physiol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3390\/pathophysiology29030038","article-title":"Critical functions of histone deacetylases (HDACs) in modulating inflammation associated with cardiovascular diseases","volume":"29","author":"Kulthinee","year":"2022","journal-title":"Pathophysiology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s40265-024-02052-1","article-title":"Givinostat: first approval","volume":"84","author":"Lamb","year":"2024","journal-title":"Drugs"},{"key":"B31","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13395-021-00273-6","article-title":"The pan HDAC inhibitor Givinostat improves muscle function and histological parameters in two Duchenne muscular dystrophy murine models expressing different haplotypes of the LTBP4 gene","volume":"11","author":"Licandro","year":"2021","journal-title":"Skelet. Muscle"},{"key":"B32","doi-asserted-by":"publisher","first-page":"690901","DOI":"10.5402\/2012\/690901","article-title":"Regulation of immune responses by histone deacetylase inhibitors","volume":"2012","author":"Licciardi","year":"2012","journal-title":"ISRN Hematol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1586\/14789450.2.5.719","article-title":"Histone structure and nucleosome stability","volume":"2","author":"Mari\u00f1o-Ram\u00edrez","year":"2005","journal-title":"Expert Rev. Proteomics"},{"key":"B34","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3389\/fgene.2011.00064","article-title":"Dystrophin orchestrates the epigenetic profile of muscle cells via miRNAs","volume":"2","author":"Marrone","year":"2011","journal-title":"Front. Gene."},{"key":"B35","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S1474-4422(24)00036-X","article-title":"Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Mercuri","year":"2024","journal-title":"Lancet Neurology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"210110","DOI":"10.1098\/rsob.210110","article-title":"Fibro-adipogenic progenitors in skeletal muscle homeostasis, regeneration and diseases","volume":"11","author":"Molina","year":"2021","journal-title":"Open Biol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1130183","DOI":"10.3389\/fmolb.2023.1130183","article-title":"Histone deacetylase functions and therapeutic implications for adult skeletal muscle metabolism","volume":"10","author":"Molinari","year":"2023","journal-title":"Front. Mol. Biosci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.molmed.2024.01.007","article-title":"HDAC inhibitors as pharmacological treatment for Duchenne muscular dystrophy: a discovery journey from bench to patients","volume":"30","author":"Mozzetta","year":"2024","journal-title":"Trends Mol. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e1462","DOI":"10.1002\/wsbm.1462","article-title":"Skeletal muscle: a review of molecular structure and function, in health and disease","volume":"12","author":"Mukund","year":"2020","journal-title":"WIREs Mech. Dis."},{"key":"B40","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s13023-017-0703-4","article-title":"Comprehensive analysis for genetic diagnosis of Dystrophinopathies in Japan","volume":"12","author":"Okubo","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"7108","DOI":"10.1038\/s41467-022-34831-3","article-title":"Pharmacological inhibition of HDAC6 improves muscle phenotypes in dystrophin-deficient mice by downregulating TGF-\u03b2 via Smad3 acetylation","volume":"13","author":"Osseni","year":"2022","journal-title":"Nat. Commun."},{"key":"B42","doi-asserted-by":"publisher","first-page":"6669","DOI":"10.1016\/j.cell.2024.08.041","article-title":"Profound cellular defects attribute to muscular pathogenesis in the rhesus monkey model of Duchenne muscular dystrophy","volume":"187","author":"Ren","year":"2024","journal-title":"Cell."},{"key":"B43","doi-asserted-by":"publisher","first-page":"299rv4","DOI":"10.1126\/scitranslmed.aaa7322","article-title":"Immune-mediated pathology in Duchenne muscular dystrophy","volume":"7","author":"Rosenberg","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13148-021-01001-z","article-title":"Epigenetic modifications in muscle regeneration and progression of Duchenne muscular dystrophy","volume":"13","author":"Rugowska","year":"2021","journal-title":"Clin. Epigenet"},{"key":"B45","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13023-017-0631-3","article-title":"The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review","volume":"12","author":"Ryder","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"B46","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1101\/gad.234468.113","article-title":"HDAC-regulated myomiRs control BAF60 variant exchange and direct the functional phenotype of fibro-adipogenic progenitors in dystrophic muscles","volume":"28","author":"Saccone","year":"2014","journal-title":"Genes. Dev."},{"key":"B47","doi-asserted-by":"publisher","first-page":"4306","DOI":"10.3390\/ijms24054306","article-title":"Histone deacetylases: molecular mechanisms and therapeutic implications for muscular dystrophies","volume":"24","author":"Sandon\u00e0","year":"2023","journal-title":"IJMS"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e50863","DOI":"10.15252\/embr.202050863","article-title":"HDAC inhibitors tune miRNAs in extracellular vesicles of dystrophic muscle\u2010resident mesenchymal cells","volume":"21","author":"Sandon\u00e0","year":"2020","journal-title":"EMBO Rep."},{"key":"B49","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1517\/21678707.2016.1130617","article-title":"HDAC inhibitors for muscular dystrophies: progress and prospects","volume":"4","author":"Sandon\u00e1","year":"2016","journal-title":"Expert Opin. Orphan Drugs"},{"key":"B50","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/cdd.2015.171","article-title":"Cell death, clearance and immunity in the skeletal muscle","volume":"23","author":"Sciorati","year":"2016","journal-title":"Cell. Death Differ."},{"key":"B51","doi-asserted-by":"publisher","first-page":"e1001888","DOI":"10.1371\/journal.pmed.1001888","article-title":"P2RX7 purinoceptor: a therapeutic target for ameliorating the symptoms of Duchenne muscular dystrophy","volume":"12","author":"Sinadinos","year":"2015","journal-title":"PLOS Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/icb.2011.88","article-title":"HDAC inhibitors: modulating leukocyte differentiation, survival, proliferation and inflammation","volume":"90","author":"Sweet","year":"2012","journal-title":"Immunol. Cell. Biol."},{"key":"B53","unstructured":"DUVYZAT (givinostat) oral suspension\n          \n          Italfarmaco S.p.A\n          Prescribing Information\n          \n          2024"},{"key":"B54","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/jcsm.12245","article-title":"Recent developments in Duchenne muscular dystrophy: facts and numbers","volume":"8","author":"Walter","year":"2017","journal-title":"J. cachexia sarcopenia muscle"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/s42003-022-03980-y","article-title":"The role of the dystrophin glycoprotein complex in muscle cell mechanotransduction","volume":"5","author":"Wilson","year":"2022","journal-title":"Commun. Biol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.3390\/ijms22063265","article-title":"The role of innate and adaptive immune cells in skeletal muscle regeneration","volume":"22","author":"Ziemkiewicz","year":"2021","journal-title":"Int. J. Mol. Sci."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2024.1514898\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T07:05:08Z","timestamp":1736147108000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2024.1514898\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":56,"alternative-id":["10.3389\/fcell.2024.1514898"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2024.1514898","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,6]]},"article-number":"1514898"}}